Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

NCT04955938 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT04955938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04955938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
Lead sponsor
University of Chicago
Phase
Phase 1
Overall status
Withdrawn
Start date
October 29, 2021
Completion date
June 7, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

blood cancer, idh mutation, idh1 mutation, idh2 gene mutation, myeloproliferative neoplasm